Tesamorelin
Tesamorelin is a GHRH analogue with comparatively strong clinical evidence for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Visceral fat surrounds internal organs and differs from fat beneath the skin.
Unlike most compounds in this category, tesamorelin has an established clinical indication for this specific population, and its use is guided by physician assessment and monitoring.
What Is Tesamorelin?
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone with a specific, well-documented clinical role.
A treating physician confirms applicable requirements in Thailand and whether the clinical indication is appropriate for you.
How Does Tesamorelin Work?
Tesamorelin stimulates pituitary GHRH receptors, increasing growth hormone secretion and IGF-1. These endocrine changes influence fat metabolism.
Clinical trials in adults with HIV-associated abdominal fat accumulation found reductions in visceral fat. Research continues to explore wider applications beyond this population.
What Has Research Studied?
Randomised trials have assessed visceral fat, body composition, metabolic measures and safety in adults with HIV. Additional studies have examined liver fat in selected patients with HIV.
Visceral fat can reaccumulate after treatment stops, which is why MRC pairs treatment with ongoing physician monitoring and lifestyle guidance.
Safety and Medical Supervision
Important concerns include increased IGF-1, glucose intolerance or diabetes, fluid retention, joint symptoms, hypersensitivity and injection-site reactions. Active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis are important contraindications.
Medical supervision includes confirming the indication, reviewing contraindications and monitoring glucose and IGF-1. Clinical response and continued treatment suitability require periodic reassessment.
Frequently Asked Questions
Is tesamorelin a general weight-loss medicine?
Its established clinical indication concerns excess abdominal fat in adults with HIV-associated lipodystrophy. A physician can advise on suitability for your goals.
Does tesamorelin reduce all abdominal fat?
Trials primarily support an effect on visceral fat in the indicated population. Fat beneath the skin does not necessarily respond in the same way.
Can visceral fat return after treatment stops?
Yes. Clinical studies found reaccumulation after discontinuation, which is why MRC pairs treatment with ongoing lifestyle and monitoring support.
What monitoring is needed?
A physician monitors glucose and IGF-1 and reviews progress regularly, tailoring monitoring to your medical history.
References
- PubMed. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
- PubMed. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
- PubMed. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Related Peptides
Wondering Whether Tesamorelin Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.